GSK plc
NYSE:GSK

  • LAST PRICE
    42.5700
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    42.4800/ 6
  • Ask / Lots
    42.5100/ 9
  • Open / Previous Close
    0.0000 / 42.5700
  • Day Range
    ---
  • 52 Week Range
    33.3300
    43.8400
  • Volume
    9,858

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract

    • 18 hours ago by MT Newswires
      Companies Mentioned: GSK, JNJ, MSFT, PFE, KKR, ADP, MA, CVS
      12:22 PM EDT, 05/01/2024 (MT Newswires) -- The Dow Jones Industrial Average was trading in plus territory, while the other two major US indexes were in the red in mid-day trading as investors awaited the conclusion of the Federal Open Market Committ...

    • 20 hours ago by Dow Jones
      Companies Mentioned: GSK

      GSK shares rose after the pharmaceutical giant raised its full-year profit guidance alongside market beating turnover and core earnings per share figures for the first quarter of the year. Earnings were boosted by vaccine sales which rose by double-digits as U.S. demand for its recently launched respiratory syncytial virus vaccine Arexvy and market growth for Shingrix in international and European markets offset the six percentage points decline in Covid-19 sales compared to the prior year period. Shares are currently up 1.8% at 1703.50 pence and 17% over the year to date. The following is a selection of reactions and comments.

    • 21 hours ago by Dow Jones
      Companies Mentioned: GSK

      1321 GMT - GSK's CEO Emma Walmsley says in a press call that she sees expansion opportunities for its respiratory syncytial virus vaccine Arexvy across patient groups and markets. GSK aims to tap into the 50-59 age group, which would expand its market potential by an additional 15 million at-risk adults in the U.S., Walmsley says. GSK hopes to receive FDA approval for this age segment in May or June to launch it in time for the next RSV season, Walmsley says. GSK posted a two-thirds market share for Arexvy through 1Q and is confident to reach its more than GBP3 billion peak-year sales forecast, she adds. Although currently mainly U.S.-led, GSK expects to further expand Arexvy internationally, Walmsley says. The vaccine generated 20% of the company's annual sales. (helena.smolak@wsj.com)

    • 21 hours ago by MT Newswires
      Companies Mentioned: GSK, IBB, JNJ, PFE, XLV
      09:03 AM EDT, 05/01/2024 (MT Newswires) -- Health care stocks were mixed pre-bell Wednesday, with the Health Care Select Sector SPDR Fund (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) recently inactive. Johnson & Johnson (JNJ) was up more...

    • 22 hours ago by Dow Jones
      Companies Mentioned: GSK

      1213 GMT - GSK's results and guidance lift signal confidence in future growth, even though its earnings saw a boost by one-off items, Barclays analysts say in a note. First-quarter earnings were supported by a reversal of last year's provision for the cancer drug Zejula litigation and a stronger royalty income from HPV drug Gardasil, Barclays says. Excluding the one-offs, adjusted operating profit would have still beaten Barclays and market expectations, the analysts add. "We can't recall a time GSK's raised the guide at 1Q, so this does make a statement[..]regarding confidence on the go?-?forward prospects," they say. GSK raised its profit guidance but left its turnover target unchanged, though the company now guides for the upper end of the range. Shares are up 2.3% at 1,711.50 pence. (helena.smolak@wsj.com)

Peers Headlines